Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.

ABSTRACT:

Background

High-dose therapy and autologous stem cell transplantation (ASCT) improves outcomes for patients with mantle cell lymphoma (MCL), but relapse ultimately occurs in most patients. Recently presented interim results from a phase III prospective trial suggest maintenance rituximab (MR) after ASCT for MCL improves progression-free survival (PFS). The maturation of these data and any benefit of MR on overall survival (OS) remain to be defined.

Patients and methods

In this retrospective study, we examined a cohort of consecutive patients with MCL that underwent ASCT for MCL at our center and evaluated their outcomes according to whether they received MR after ASCT (n = 50) or did not (n = 107). MR was treated as a time-dependent covariate to account for variation in timi

SUBMITTER: Graf SA 

PROVIDER: S-EPMC4621031 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature